Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3
Journal of Gynecologic Oncology · 2023
DOI: 10.3802/jgo.2023.34.e51 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gynecologic Oncology, 2023. Verfasst von Jung-Yun Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Genital Neoplasms, Female, Antineoplastic Agents, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In the 2022 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Ovarian cancer: long-term follow-up data, new poly (ADP-ribose) polymerase (PARP) inhibitors, overall survival (OS) issues with PARP inhibitor monotherapy, hyperthermic intraperitoneal chemotherapy, immunotherapy, and antibody-drug conjugate; 2) Cervical cancer: surgery in early stage disease, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Corpus cancer: follow-up regimen, immune checkpoint inhibitor, WEE1 inhibitor, selective inhibitor of nuclear export. A special note was made on the withdrawal of PARP inhibitor from the market for heavily pretreated ovarian cancer patients based on the final OS results of ARIEL-4 and SOLO-3 due to concerns of increased risk of death.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
- Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
- Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea.
- Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea.
- Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea.
ORCID-Profile: Jung-Yun Lee, Yoo-Young Lee, Jeong-Yeol Park, Seung-Hyuk Shim, Se Ik Kim, Tae-Wook Kong, Chul Kwon Lim, Hyun Woong Cho, Dong Hoon Suh
Zitieren
APA
Lee, J. Y., Lee, Y. Y., Park, J. Y., Shim, S. H., Kim, S. I., Kong, T. W., Lim, C. K., Cho, H. W., & Suh, D. H. (2023). Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2023.34.e51
Vancouver
Lee JY, Lee YY, Park JY, Shim SH, Kim SI, Kong TW, et al. Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3. Journal of Gynecologic Oncology. 2023. doi:10.3802/jgo.2023.34.e51
BibTeX
@article{Lee2023,
author = {Lee, Jung-Yun and Lee, Yoo-Young and Park, Jeong-Yeol and Shim, Seung-Hyuk and Kim, Se Ik and Kong, Tae-Wook and Lim, Chul Kwon and Cho, Hyun Woong and Suh, Dong Hoon},
title = {Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3},
journal = {Journal of Gynecologic Oncology},
year = {2023},
doi = {10.3802/jgo.2023.34.e51}
}
EUVIMED